Abstract
Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Herberman RB, Reynolds CW, Ortaldo JR: Mechanism of cytotoxicity by natural killer (NK) cell. Annu Rev Immunol 4:651-680, 1986
Doherty PC, Christensen JP: Accessing complexity: The dynamics of virus-specific T-cell responses. Annu Rev Immunol 18:561-592, 2000
Ostrand-Rosenberg S: Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr Opin Immunol 6:722-727, 1994
Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P, Hansson J, Sjogren HO: Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human cells. J Immunol 144:4663-4669, 1990
Gjorloff A, Fischer H, Hedlund G, Hansson J, Kenney JS, Allison AC, Sjogren HO, Dohlsten M: Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T-cells. Cell Immunol 137:61-71, 1991
Johnson HM, Russell JK, Pontzer CH: Staphylococcal enterotoxin microbial superantigens. FASEB J 5:2706-2712, 1991
Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forberg C, Lind P, Kalland T: Monoclonal abtibody-superabtigen fusion protein: Tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 91:8945-8949, 1994
Ihle J, Holzer U, Krull F, Dohlsten M, Kalland T, Niethammer D, Dannecker GE: Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res 55: 623-628, 1995
Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T: Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 92:9791-9795, 1995
Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M: Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 68:109-113, 1996
Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M: Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313, 1998
Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M: Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 81:156-163, 1999
Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26:1-9, 1996
Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986
Sharpe S, Barber KR, Grant CW: Val (659)-Glu mutation within the transmembrane domain of ErbB-2: Effects measured by (2)H NMR in fluid phospholipid bilayers. Biochemistry 39:6572-6580, 2000
Ma W, Yu H, Wang Q, Bao J, Yan J, Jin H: In vitro Biological activities of transmembrane superantigen Staphylococcal Enterotoxin A fusion protein. Cancer Immunol Immunother 53:118-124, 2004
Kim SY, Lee SE, Kim YR, Kim CM, Ryu PY, Choy HE, Chung SS, Rhee JH: Regulation of Vibrio vulnificus virulence by the LuxS quorum-sensing system. Mol Microbiol 48:1647-1664, 2003
Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS: Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9:1906-1916, 2003
Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH: Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119-126, 2000
Diefenbach A, Jensen ER, Jamieson AM, Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171, 2001
Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97:2731-2736, 2000
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100, 2002
Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300, 1999
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203, 2000
Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995
Ruiz-Cabello F, Garrido F: HLA and cancer: From research to clinical impact. Immunol Today 19:539-542, 1998
Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750-1758, 1998
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26:1-9, 1996
Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Sogaard M, Andersson J, Andersson U: The distinct role of CD4+ and CD8+ T-cells during the anti-tumor effects of targeted superantigens. Br J Cancer 81:359-366, 1999
Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M: Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313, 1998
Nielsen SE, Zeuthen J, Lund B, Persson B, Alenfall J, Hansen HH: Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma. J Immunother 23:146-153, 2000
Wahlsten JL, Mills CD, Ramakrishnan S: Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 161:6761-6767, 1998
Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X: Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol 127:718-726, 2001
Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL, Dohlsten M: Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 85:129-136, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ma, W., Yu, H., Wang, Q. et al. A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity. J Clin Immunol 24, 294–301 (2004). https://doi.org/10.1023/B:JOCI.0000025451.41948.94
Issue Date:
DOI: https://doi.org/10.1023/B:JOCI.0000025451.41948.94